Livalo® (pitavastatin) – Expanded indication
May 16, 2019 - The FDA approved Kowa Pharmaceuticals’ Livalo (pitavastatin), as an adjunctive therapy to diet in pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B).
Top